5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week

Chart, Trading, Forex, Analysis, Tablet, Pc

Image Source: Pixabay

The 5 constituents in the munKNEE Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD. Below is how each constituent stock performed last week, in descending order, and MTD, and any recent news, commentary, and/or analysis on each company:

Compass Pathways (CMPS): UP 33.1% last week; UP 22.2% MTD
- is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Latest News, Commentary and/or Analysis:
  - None
GH Research (GHRS): UP 23.9% last week; UP 25.0% MTD
- is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
- Latest News, Commentary and/or Analysis:
  - Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?
Mind Medicine (MNMD): UP 2.8% last week; UP 0.8% MTD
- is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
- Latest News, Commentary and/or Analysis:
  - MindMed Announces Business Update and Anticipated Milestones for 2024
Atai Life Sciences (ATAI): UP 1.2% last week; UP 22.0% MTD
- is focused on the use of ketamine, DMT and ibogaine. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- Latest News, Commentary and/or Analysis:
  - None
Incannex Healthcare (IXHL): DOWN 7.4% last week; DOWN 19.4% MTD
- is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
- Latest News, Commentary and/or Analysis:
  - Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis